Document Detail

N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.
MedLine Citation:
PMID:  18092166     Owner:  NLM     Status:  MEDLINE    
Systemic sclerosis (SSc) is characterized by vascular dysfunction that may lead to pulmonary artery hypertension (PAH). The N-terminal pro-B type natriuretic peptide (NT-proNBP), a marker of cardiac failure, is a diagnostic marker of early PAH in patients with SSc without heart failure. Our aim was to determine whether NT-proBNP levels may be a useful tool to evaluate the response to bosentan therapy in patients with PAH secondary to SSc. Ten patients with symptomatic, severe PAH secondary to SSc, received bosentan, 62.5 mg twice a day for 4 weeks followed by 125 mg twice a day for 7 months. Ten patients with SSc without PAH served as controls for basal level of NT-proBNP. Blood samples were obtained before the beginning of the therapy and after 3 and 7 months of treatment. SSc patients with PAH had significantly higher serum levels of NT-proBNP than those without PAH, at baseline. After 3 and 7 months of therapy, NT-proBNP concentration showed a progressive decrease, nearly approaching statistical difference at 7 months when compared to baseline levels (P=0.953 and P=0.600). Our results show that serum NT-proBNP levels may be a useful marker for the response to bosentan therapy in patients with PAH secondary to SSc.
Sara Simeoni; Giuseppe Lippi; Antonio Puccetti; Martina Montagnana; Elisa Tinazzi; Daniele Prati; Roberto Corrocher; Claudio Lunardi
Related Documents :
8102776 - Soluble cd23 in human immunodeficiency virus type 1 infected patients.
11891606 - Different expression of endothelin in the bronchoalveolar lavage in patients with pulmo...
12818056 - Relevance of plasma d-dimer measurement in patients with acute peripheral vertigo.
6136696 - Raised plasma metenkephalin in patients who habitually mutilate themselves.
18077496 - High-frequency ultrasound of skin involvement in systemic sclerosis reflects oedema, ex...
20482406 - Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment.
Publication Detail:
Type:  Journal Article     Date:  2007-12-19
Journal Detail:
Title:  Rheumatology international     Volume:  28     ISSN:  0172-8172     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-08     Completed Date:  2008-07-24     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  657-60     Citation Subset:  IM    
Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, Policlinico GB Rossi, P.le LA Scuro 37134, Verona, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hypertension, Pulmonary / blood,  drug therapy*
Middle Aged
Natriuretic Peptide, Brain / blood*
Peptide Fragments / blood*
Scleroderma, Systemic / blood,  complications*
Sulfonamides / therapeutic use*
Reg. No./Substance:
0/Peptide Fragments; 0/Sulfonamides; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain; Q326023R30/bosentan
Comment In:
Rheumatol Int. 2009 Jan;29(3):347-8   [PMID:  18690444 ]
Rheumatol Int. 2008 Nov;29(1):115   [PMID:  18500454 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cutaneous vasculitis as an initiating paraneoplastic symptom in Hodgkin lymphoma.
Next Document:  TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus.